Coherus BioSciences Inc. (NASDAQ:CHRS)’s share price was up 15.7% on Monday . The stock traded as high as $20.00 and last traded at $19.92, with a volume of 881,450 shares trading hands. The stock had previously closed at $17.22.

Separately, Zacks Investment Research lowered Coherus BioSciences from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th.

The stock’s market cap is $843.84 million. The stock has a 50 day moving average of $17.01 and a 200-day moving average of $17.84.

Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings data on Monday, May 9th. The company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.42) by $0.25. On average, equities analysts anticipate that Coherus BioSciences Inc. will post ($5.90) earnings per share for the current year.

In related news, insider Alan C. Herman sold 4,250 shares of the stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $19.20, for a total transaction of $81,600.00. Following the completion of the transaction, the insider now directly owns 207,167 shares of the company’s stock, valued at $3,977,606.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter K. Watler sold 12,000 shares of the stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $20.00, for a total transaction of $240,000.00. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently bought and sold shares of CHRS. CAM Group Holding A S boosted its position in Coherus BioSciences by 17.7% in the fourth quarter. CAM Group Holding A S now owns 146,000 shares of the company’s stock valued at $3,352,000 after buying an additional 22,000 shares in the last quarter. Brown Advisory Inc. boosted its position in Coherus BioSciences by 3.0% in the fourth quarter. Brown Advisory Inc. now owns 200,918 shares of the company’s stock valued at $4,614,000 after buying an additional 5,937 shares in the last quarter. Columbus Circle Investors boosted its position in Coherus BioSciences by 33.0% in the fourth quarter. Columbus Circle Investors now owns 276,752 shares of the company’s stock valued at $6,354,000 after buying an additional 68,666 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in Coherus BioSciences by 3.1% in the fourth quarter. Jennison Associates LLC now owns 367,021 shares of the company’s stock valued at $8,427,000 after buying an additional 11,023 shares in the last quarter.

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.